BenevolentAI Investor Conference Presentation Deck
AstraZeneca
THERAPEUTIC AREAS
2019 - INITIAL DEAL
Chronic kidney
disease (CKD)
GO
2022 - EXPANSION
(3 year collaboration)
Heart failure
Idiopathic
pulmonary
fibrosis (IPF)
Systemic lupus
erythematosus (SLE)
RECENT POSITIVE DEVELOPMENTS
May 2023
New preclinical data on one of the IPF
targets presented by AZ at American
Thoracic Society (ATS)
Collaboration with AstraZeneca
continues to progress
●
End-to-End Drug Discovery
Multi-year Target-ID collaboration delivering novel
targets for complex diseases
• Deal structure of upfront fee, milestone payments
and downstream royalties
• AZ progressing four most promising targets from
five initially selected in CKD and IPF
• Further target selection opportunities in Heart
Failure and SLE
BenevolentAl Proprietary
Benevolent
LO
5View entire presentation